Overall, these findings establish exosomal S100A9 as a crucial mediator of TME reprogramming, suggesting that targeting the S100A9-IL-17 axis may serve as a promising therapeutic strategy for disrupting ACC lung metastasis. The gene discussed is IL17A; the disease is adrenal cortex carcinoma.